Prostatype Genomics AB (OSTO:PROGEN) Debt-to-Asset : 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
14 GF Score
Price kr0.15
GF Value kr0.15
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Debt-to-Asset?

Prostatype Genomics AB OSTO:PROGEN +3.40% 14 Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus rates OSTO:PROGEN with a GF Score™ of 14/100 and a GF Value™ of kr0.15 (Fairly Valued). The stock has 6 warning signs investors should review.

Prostatype Genomics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr0.00 Mil. Prostatype Genomics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr0.00 Mil. Prostatype Genomics AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was kr39.91 Mil. Prostatype Genomics AB's debt to asset for the quarter that ended in Jun. 2026 was 0.00.

Prostatype Genomics AB  (OSTO:PROGEN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Prostatype Genomics AB Debt-to-Asset Related Terms

Prostatype Genomics AB Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Debt-to-Asset Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.03 0.03 0.24 0.00 0.10

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.10 0.00

OSTO:PROGEN vs TMO, DHR, NTRA: Debt-to-Asset Comparison

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prostatype Genomics AB Debt-to-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Debt-to-Asset falls into.


OSTO:PROGEN
14GF Score
Prostatype Genomics AB OSTO:PROGEN
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Prostatype Genomics AB's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5.3 + 0) / 50.862
=0.10

Prostatype Genomics AB's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 39.912
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Debt-to-Asset of 0.00 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Debt-to-Asset too high?
Prostatype Genomics AB's current Debt-to-Asset is 0.00. Overall, Prostatype Genomics AB has a GF Score™ of 14/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Debt-to-Asset compare to TMO and DHR?
Prostatype Genomics AB's Debt-to-Asset of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Diagnostics & Research company?
A good Debt-to-Asset depends on the Medical Diagnostics & Research industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Fairly Valued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.15 — trading 1.3% above its estimated fair value. The current Debt-to-Asset is 0.00. Prostatype Genomics AB's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.15 is trading 1.3% above its estimated GF Value™ of kr0.15. GuruFocus considers Prostatype Genomics AB to be Fairly Valued.

Key valuation signals for OSTO:PROGEN:

  • Debt-to-Asset: 0.00
  • GF Value™: kr0.15 vs. price of kr0.15 (1.3% above fair value)
  • GF Score™: 14/100 with 6 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Other Exchanges PGO0:Germany
Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
14GF Score

Get the complete analysis for OSTO:PROGEN

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.15
Price
kr0.15
GF Value